Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Receivables: 2024-2025

Historic Receivables for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $35.9 million.

  • Kura Oncology's Receivables was N/A to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.3 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Receivables stood at $35.9 million for Q3 2025, which was up 685.66% from $4.6 million recorded in Q2 2025.
  • Kura Oncology's 5-year Receivables high stood at $48.7 million for Q1 2025, and its period low was $2.1 million during Q4 2024.